These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8020047)

  • 21. Mechanisms by which K(ATP) channel openers produce acute and delayed cardioprotection.
    Wang Y; Haider HK; Ahmad N; Ashraf M
    Vascul Pharmacol; 2005; 42(5-6):253-64. PubMed ID: 15922258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similarities between ischemic preconditioning and 17beta-estradiol mediated cardiomyocyte KATP channel activation leading to cardioprotective and antiarrhythmic effects during ischemia/reperfusion in the intact rabbit heart.
    Das B; Sarkar C
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):277-86. PubMed ID: 16495767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving Issues in the Treatment of Angina Pectoris. Nicorandil: The 1st Potassium-Channel Activator in Ischemic Heart Disease. Proceedings of an International Workshop. Taormina, Sicily, May 8-12, 1991.
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S1-108. PubMed ID: 1282167
    [No Abstract]   [Full Text] [Related]  

  • 24. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
    Tosaki A; Szerdahelyi P; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Nicorandil, as ATP-sensitive K+ channel opener, potentiated morphine analgesia].
    Asano T; Iida H; Dohi S; Masue T; Shimonaka H
    Masui; 1996 Nov; 45(11):1342-6. PubMed ID: 8953867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of nicorandil preconditioning on membrane dystrophin.
    Shojima T; Hayashida N; Nishi A; Takagi K; Hori H; Yoshikawa K; Aoyagi S
    Eur J Cardiothorac Surg; 2006 Sep; 30(3):472-9. PubMed ID: 16859916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-generation sulfonylureas preserve inhibition of mitochondrial permeability transition by the mitochondrial K+(ATP) opener nicorandil in experimental myocardial infarction.
    Argaud L; Garrier O; Loufouat J; Gomez L; Couture-Lepetit E; Gateau-Roesch O; Robert D; Ovize M
    Shock; 2009 Sep; 32(3):247-52. PubMed ID: 19174741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation.
    Penna C; Rastaldo R; Mancardi D; Raimondo S; Cappello S; Gattullo D; Losano G; Pagliaro P
    Basic Res Cardiol; 2006 Mar; 101(2):180-9. PubMed ID: 16450075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective mitochondrial adenosine triphosphate-sensitive potassium channel activation is sufficient to precondition human myocardium.
    Pomerantz BJ; Robinson TN; Morrell TD; Heimbach JK; Banerjee A; Harken AH
    J Thorac Cardiovasc Surg; 2000 Aug; 120(2):387-92. PubMed ID: 10917958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Potassium agonists].
    Hellwig B
    Med Monatsschr Pharm; 1994 Jun; 17(6):164-7. PubMed ID: 8052166
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of temperature on the activation of myocardial KATP channel in guinea pig ventricular myocytes: a pilot study by whole cell patch clamp recording.
    Jin SQ; Niu LJ; Deng CY; Yao ZB; Zhou YJ
    Chin Med J (Engl); 2006 Oct; 119(20):1721-6. PubMed ID: 17097020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potassium channels as pharmacological targets in cardiovascular medicine.
    Escande D; Henry P
    Eur Heart J; 1993 Jul; 14 Suppl B():2-9. PubMed ID: 8370367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiologic effects of potassium channel openers.
    Haverkamp W; Borggrefe M; Breithardt G
    Cardiovasc Drugs Ther; 1995 Mar; 9 Suppl 2():195-202. PubMed ID: 7647023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NICORANDIL EFFICACY IN THE TREATMENT OF ISCHEMIC HEART DISEASE (REVIEW).
    Gvishiani M; Gabunia L; Makharadze T; Gongadze N
    Georgian Med News; 2018; (280-281):152-155. PubMed ID: 30204115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in macrophage free radical and tumor necrosis factor production by a potassium channel activator.
    Pogrebniak HW; Matthews W; Pass HI
    J Surg Res; 1992 Apr; 52(4):395-400. PubMed ID: 1534387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. K+ channel openers and 'natural' cardioprotection.
    Escande D; Cavero I
    Trends Pharmacol Sci; 1992 Jul; 13(7):269-72. PubMed ID: 1509521
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting solid tumours with potassium channel activators. A return to fundamentals?
    Trechot P
    Therapie; 2014; 69(6):533-4. PubMed ID: 25371295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anilide tertiary carbinols: a novel series of K+ channel openers.
    Grant TL; Ohnmacht CJ; Howe BB
    Trends Pharmacol Sci; 1994 Nov; 15(11):402-4. PubMed ID: 7855900
    [No Abstract]   [Full Text] [Related]  

  • 39. Potassium channel openers. Pharmacological effects and future uses.
    Duty S; Weston AH
    Drugs; 1990 Dec; 40(6):785-91. PubMed ID: 2078995
    [No Abstract]   [Full Text] [Related]  

  • 40. [K-channel activators and cardioprotection].
    Specchia G; Marsico F; Laudisa ML
    Cardiologia; 1993 Dec; 38(12 Suppl 1):453-7. PubMed ID: 8020047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.